1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
AHN-GOOK PHARMACEUTICAL Co., Ltd.

AHN-GOOK PHARMACEUTICAL Co., Ltd.

KKRX:001540
9,250.00
KRW
-90.00
(-0.96%)
1,426.30EPS
5.41P/E
88.08BMarket Cap
AHN-GOOK PHARMACEUTICAL Co., Ltd.
KRX:001540
(Korea Stock Exchange)

Recent

price

9,250.00

P/E

ratio

5.41

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
10,335.5
12,415.01
13,820.71
14,836.22
14,849.79
17,272.87
15,217.71
16,021.69
16,214.12
13,583.78
12,533.96
14,280.92
18,043.31
20,648.38
23,851.75
26,992.75
29,039.95
Revenue per Share
1,429.88
618.17
345.91
628.71
-121
818
150
712
1,154
221
-115
344
604
114
1,482
658
1,431.34
Basic EPS, GAAP
290.33
-1,031.38
872.89
-291.13
-569.36
1,420.46
717.46
1,064.05
-362.59
1,598.44
-1,162.76
-322.29
-174.81
-667.7
-6,280.23
3,255.82
3,647.27
Free Cash Flow per Basic Share
93.53
94.59
98.26
121.36
196.62
198.13
220.44
219.98
220.06
219.73
220.41
220.15
220.6
220.94
219.97
439.87
- -
Dividend per Share
9,508.86
10,596.51
10,835.87
11,211.02
10,733.78
11,439.51
11,423.53
11,951.85
12,807.77
12,936.96
13,035.9
13,441.11
13,620.13
13,381.56
14,577.25
14,550.79
14,946.33
Book Value per Share
9,500.69
10,215.79
10,411.29
10,862.75
10,470.37
11,167.4
11,196.03
11,733.43
12,448.47
12,624.62
12,741.09
13,101.72
13,260.57
13,004.33
14,233.98
13,798.11
14,211.23
Tangible Book Value per Share
10
10
10
10
11
11
11
11
11
11
11
11
11
11
11
11
11
Basic Weighted Avg Shares
108,204
129,946
140,828
153,972
167,936
197,736
174,002
183,600
185,746
155,852
143,364
163,534
205,389
233,676
271,116
306,874
330,050
Sales/Revenue/Turnover
15.43
9.39
3.9
6.74
5.84
6.54
2.39
5.67
8.27
1.55
0.66
-0.66
4.46
2.14
2.47
3.2
6.06
Operating Margin (%)
1,725
2,080
2,178
2,160
2,800
2,869
3,168
3,376
3,263
3,854
4,683
4,507
4,930
5,023
7,698
8,778
8,952
Depreciation Expense
14,970
6,470
3,525
6,525
-1,368
9,364
1,715
8,159
13,220
2,536
-1,315
3,939
6,875
1,290
16,845
7,481
16,268
Net Income, GAAP
10.13
32.32
8.42
14.31
112.22
23.45
14.6
34.63
19.48
1.55
278.43
1.62
6.73
76.61
19.25
5.15
14.4
Effective Tax Rate (%)
13.83
4.98
2.5
4.24
-0.81
4.74
0.99
4.44
7.12
1.63
-0.92
2.41
3.35
0.55
6.21
2.44
4.93
Profit Margin (%)
59,020
69,532
69,029
80,077
76,841
99,831
71,639
74,827
96,699
95,857
66,754
64,072
60,511
57,174
57,713
53,842
57,723
Working Capital
2,926
747
751
785
3,215
14,628
1,772
746
568
548
402
234
210
120
50,227
50,444
50,416
LT Debt
99,553
112,085
114,363
126,422
122,465
131,894
131,347
137,453
147,219
148,358
149,425
153,281
154,671
151,666
164,743
166,289
170,809
Total Equity
13.54
5.78
3.78
6.49
-0.85
6.53
2.27
4.38
7.76
1.44
0.07
-0.66
5.49
0.71
2.63
3.87
6.97
Return on Invested Capital (%)
14.53
5.53
3.25
5
-0.98
7.04
1.83
5.52
8.5
2.29
-1.49
2.47
4.03
0.94
9.6
4.26
7.61
Return on Capital (%)
16.2
6.13
3.13
5.45
-1.11
7.41
1.31
6.09
9.32
1.72
-0.88
2.6
4.46
0.84
10.6
4.52
9.78
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
22,499
22,631
27,642
LT Borrowings
50,000
50,117
50,100
LT Finance Leases
308
327
317
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
88,650
96,151
88,082

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
134,335
136,765
151,056
Cash, Cash Equivalents & STI
53,176
54,050
66,335
Accounts Receivable, Net
33,586
28,598
33,979
Inventories
45,652
51,367
47,343
Total Current Liabilities
74,976
82,923
93,333
Payables & Accruals
- -
- -
- -
ST Debt
22,499
22,631
27,642
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.4%
2.22%
0.94%
Free Cash Flow
0.53%
170.85%
-151.85%
Net Income, GAAP
86.73%
148.79%
-55.59%
Sales/Revenue/Turnover
5.32%
16.53%
13.19%
Total Cash Common Dividend
- -
- -
100%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65,739
67,177
67,508
70,693
271,116
2025
75,752
76,823
77,690
76,609
306,874
2026
98,928
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
686
848
-36
-16.02
1,482
2025
315
273.66
296.11
-227.04
658
2026
1,088.62
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
219.97
2025
- -
- -
- -
- -
439.87
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
AHN-GOOK PHARMACEUTICAL Co., Ltd. is a South Korea-based biopharmaceutical company engaged in the research, development, manufacture, and commercialization of prescription pharmaceuticals, over-the-counter medicines, health functional foods, and healthcare solutions. Founded in 1955 and headquartered in Gwacheon-si, Gyeonggi-do, South Korea, the company operates advanced manufacturing facilities in Hyangnam, Hwaseong-si, alongside dedicated research and development institutes. The company operates primarily within human therapeutics, focusing on respiratory, cardiovascular, gastrointestinal, ophthalmic, and metabolic disease management. The company's core product portfolio encompasses respiratory agents, including Synatura Syrup, a natural herbal expectorant and antitussive formulation for acute upper respiratory infections and chronic bronchitis, and Anycough capsules; cardiovascular therapies, including Levotension and Levosartan for the treatment of hypertension, as well as Pevarozet for dyslipidemia management; gastrointestinal products, including Letopra; antihistamines and allergy treatments, including Rupafin; ophthalmic treatments and health supplements, including the Tobicom product line; and active pharmaceutical ingredients and diagnostic products developed through its affiliate network, which includes AGBIO Diagnostics, Ahn-gook Newpharm, and Anguk Health. The company distributes its products to general hospitals, clinics, and retail pharmacies across South Korea while expanding export operations to international markets in Southeast Asia, Central America, and the Middle East. In recent operational and strategic developments under its long-term growth vision, Ahn-Gook Pharmaceutical entered into an exclusive domestic licensing and distribution agreement with George Medicines to commercialize WIDAPLIK (GMRx2), an innovative triple-combination therapy indicated for initial hypertension management. The company also signed a strategic research memorandum of understanding with Cellbion Co., Ltd. to jointly develop next-generation targeted radiopharmaceuticals and cancer therapy platforms. Expanding beyond traditional therapeutics, Ahn-Gook Pharmaceutical diversified into the advanced medical materials sector through a strategic partnership with SOFNT, completed the acquisition of Dimedi Korea to broaden its footprint in health technology and consumer healthcare segments, established a strategic bio-health investment fund in partnership with Mirae Asset Capital, and completed the relocation of its corporate headquarters and central research laboratories to the Gwacheon Knowledge and Information Town to consolidate administrative and research operations across its affiliated entities.